MCID: SBC017
MIFTS: 34

Sebaceous Gland Disease

Categories: Skin diseases, Endocrine diseases

Aliases & Classifications for Sebaceous Gland Disease

MalaCards integrated aliases for Sebaceous Gland Disease:

Name: Sebaceous Gland Disease 12 14
Sebaceous Gland Diseases 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9098
ICD10 33 L70.8
ICD9CM 35 706.1
UMLS 69 C0029485

Summaries for Sebaceous Gland Disease

Disease Ontology : 12 A skin disease that is located in the sebaceous gland.

MalaCards based summary : Sebaceous Gland Disease, also known as sebaceous gland diseases, is related to acne and mycobacterium malmoense, and has symptoms including exanthema and pruritus. An important gene associated with Sebaceous Gland Disease is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Development NOTCH1-mediated pathway for NF-KB activity modulation and Bacterial infections in CF airways. The drugs Benzoyl peroxide and Clindamycin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and brain.

Wikipedia : 72 Sebaceous glands are microscopic exocrine glands in the skin that secrete an oily or waxy matter, called... more...

Related Diseases for Sebaceous Gland Disease

Diseases related to Sebaceous Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
id Related Disease Score Top Affiliating Genes
1 acne 10.9
2 mycobacterium malmoense 10.5 CXCL8 TLR2
3 mycobacterium xenopi 10.5 CXCL8 TLR2
4 halal setton wang syndrome 10.5 CXCL8 TLR2
5 mycobacterium kansasii 10.5 CXCL8 TLR2
6 tumefactive multiple sclerosis 10.4 CXCL8 TLR2
7 bullous retinoschisis 10.4 CXCL8 DEFB4A
8 lung sarcoma 10.4 IER3IP1 IL1A
9 skin disease 10.4 CXCL8 DEFB4A
10 allergic bronchopulmonary aspergillosis 10.3 CXCL8 IER3IP1
11 pityriasis rosea 10.3 IER3IP1 TLR2
12 lymph node palisaded myofibroblastoma 10.3 CXCL8 IL1A
13 epulis 10.2 CXCL8 NPS
14 lip cancer 10.2 CXCL8 PSTPIP1
15 lipoid nephrosis 10.2 DEFB4A IL1A
16 thymus clear cell carcinoma 10.2 CXCL8 DEFB4A TLR2
17 testicular infarct 10.2 CXCL8 TLR2
18 myofascial pain syndrome 10.1 CXCL8 IL1A
19 survival motor neuron spinal muscular atrophy 10.1 IER3IP1 IGF1 SHBG
20 myopathy 10.0 CXCL8 PSTPIP1
21 benign dermal neurilemmoma 10.0 NCSTN PSENEN
22 vulva fibroepithelial polyp 10.0 CXCL8 IL1A TLR2
23 sclerosing cholangitis 10.0 CXCL8 DEFB4A IL1A
24 germ cell and embryonal cancer 9.9 CXCL8 DEFB4A IL1A
25 female reproductive system disease 9.9 NCSTN PSENEN
26 leptospirosis 9.8 NCSTN PSENEN
27 scleroperikeratitis 9.8 NCSTN PSENEN PSTPIP1
28 spastic entropion 9.8 IER3IP1 IL1A
29 palmoplantar keratosis 9.7 CXCL8 DEFB4A IL1A TLR2
30 inappropriate adh syndrome 9.7 CXCL8 DEFB4A IL1A TLR2
31 histiocytic and dendritic cell cancer 9.3 CXCL8 DEFB4A IGF1 IL1A
32 acute erythroid leukemia 8.0 CXCL8 DEFB4A IL1A NCSTN PSENEN PSTPIP1
33 granuloma inguinale 5.7 AARS ADSL CXCL8 DEFB4A IER3IP1 IGF1

Graphical network of the top 20 diseases related to Sebaceous Gland Disease:



Diseases related to Sebaceous Gland Disease

Symptoms & Phenotypes for Sebaceous Gland Disease

UMLS symptoms related to Sebaceous Gland Disease:


exanthema, pruritus

Drugs & Therapeutics for Sebaceous Gland Disease

Drugs for Sebaceous Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 207)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2 94-36-0 7187
2
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 18323-44-9 29029
3
Ciclopirox Approved, Investigational Phase 4,Phase 3 29342-05-0 2749
4
Isotretinoin Approved Phase 4,Phase 1 4759-48-2 5538 5282379
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
6
Salicylic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 69-72-7 338
7
Tazarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 118292-40-3 5381
8
Azelaic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 123-99-9 2266
9
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 564-25-0 54671203
10
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 1 80-08-0 2955
11
Adapalene Approved Phase 4,Phase 3,Phase 2,Phase 1 106685-40-9 60164
12
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
13
Desogestrel Approved Phase 4 54024-22-5 40973
14
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
15
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
16
Moxifloxacin Approved, Investigational Phase 4,Phase 1 354812-41-2, 151096-09-2 152946
17
Norgestimate Approved Phase 4,Phase 1 35189-28-7 6540478
18
Norgestrel Approved Phase 4 6533-00-2 13109
19
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
20
Cyproterone Acetate Approved, Investigational Phase 4,Phase 3 427-51-0
21
Coal tar Approved Phase 4 8007-45-2
22
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2 10118-90-8 5281021
23
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
24
Ketoconazole Approved, Investigational Phase 4,Phase 3 65277-42-1 47576 3823
25
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
26
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 302-79-4 5538
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
28
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
29
Nicotinamide Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
30
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 1 58-05-9 143 6006
31 tannic acid Approved, Nutraceutical Phase 4
32 Nadifloxacin Investigational Phase 4,Phase 3 124858-35-1
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
35 Clindamycin palmitate Phase 4,Phase 3,Phase 1,Phase 2
36 Clindamycin phosphate Phase 4,Phase 3,Phase 1,Phase 2
37 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1
38 Keratolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
40 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
41 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2
42 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
44 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Salicylates Phase 4,Phase 3,Phase 1,Phase 2
48 Antimalarials Phase 4,Phase 3,Phase 1,Phase 2
49 Antiparasitic Agents Phase 4,Phase 3,Phase 1,Phase 2
50 Antiprotozoal Agents Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 353)

id Name Status NCT ID Phase Drugs
1 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
2 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
3 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
4 Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
5 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris Completed NCT00835198 Phase 4 Dapsone; Tretinoin;Tretinoin
6 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris Completed NCT00834210 Phase 4 Dapsone;Tazarotene
7 A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne Completed NCT01231334 Phase 4 Dapsone plus Adapalene;Clindamycin/benzoyl peroxide plus Adapalene
8 Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris Completed NCT02721173 Phase 4 Tazarotene 0.1% gel plus clindamycin 1% gel;Adapalene 0.1% gel plus clindamycin 1% gel
9 Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris Completed NCT02589405 Phase 4 Benzoyl Peroxide
10 DUAC® Early Onset Efficacy Study in Japanese Subjects Completed NCT02557399 Phase 4 Duac® fixed dose combination gel;ADA 0.1% gel;CLDM 1% gel
11 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne Completed NCT02524665 Phase 4
12 A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris Completed NCT02249104 Phase 4 Adapalene/benzoyl peroxide gel, 0.1%/2.5%
13 Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris Completed NCT02058628 Phase 4 Clindamycin + BPO;Azelaic acid
14 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Completed NCT02032407 Phase 4 Dapsone Gel
15 Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Completed NCT01951417 Phase 4 Adapalene/BPO Gel
16 Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Completed NCT01885910 Phase 4 Doxycycline 100mg;Aczone 5% gel
17 U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne Completed NCT01706263 Phase 4
18 U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™ Completed NCT01706250 Phase 4
19 Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel Completed NCT01522456 Phase 4 Epiduo Gel;Retin-A Micro Microsphere 0.1%
20 Effect of Samples on Acne Treatment With Epiduo® Gel Completed NCT01504204 Phase 4 Adapalene + benzoyl peroxide samples;Adapalene + benzoyl peroxide from standard tube
21 An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment Completed NCT01466673 Phase 4 Ethinyl estradiol/Norgestimate (EE/NGM);Ethinyl estradiol/Desogestrel (EE/DSG)
22 A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory Completed NCT01404130 Phase 4 Isotretinoin
23 Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin Completed NCT01387048 Phase 4 skinoren;differin;skinoren
24 A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products Completed NCT01313728 Phase 4 Dapsone plus Tretinoin Gel;Tretinoin Gel
25 Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris Completed NCT01209949 Phase 4 Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
26 Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel Completed NCT01188538 Phase 4 Epiduo gel;BPO
27 Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris Completed NCT01149330 Phase 4 Adapalene-BPO Gel
28 Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris Completed NCT01047189 Phase 4 clindamycin phosphate 1.2% and tretinoin 0.025%;clindamycin 1% gel;tretinoin 0.025% cream
29 A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris Completed NCT01016977 Phase 4 Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene;clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
30 Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications Completed NCT01015638 Phase 4 Clindamycin and BPO 5% gel;Clindamycin phosphate and benzoyl peroxide 2.5% gel.
31 Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications Completed NCT00964366 Phase 4 clindamycin and benzoyl peroxide;Dapsone gel
32 A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne Completed NCT00964223 Phase 4 Clindamycin and benzoyl peroxide gel (Duac® Topical Gel);benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
33 Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00952523 Phase 4 Tretinoin Facial Gel;Adapalene/Benzoyl Peroxide Facial Gel
34 Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications Completed NCT00926367 Phase 4 Clindamycin and benzoyl peroxide;benzoyl peroxide 2.5% and adapalene 0.1% gel
35 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00919191 Phase 4 Tretinoin gel;Adapalene and Benzoyl peroxide
36 A Study of Different Use Regimens Using Two Acne Treatments Completed NCT00907257 Phase 4 benzoyl peroxide wash;Tretinoin gel
37 A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne Completed NCT00887484 Phase 4 BENZOYL PEROXIDE/ CLINDAMYCIN;BENZOYL PEROXIDE/ ADAPALENE
38 Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne Completed NCT00841776 Phase 4 Duac;Ziana gel
39 Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne Completed NCT00807014 Phase 4 Duac Gel;Differin gel
40 Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring Completed NCT00795327 Phase 4
41 Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris Completed NCT00757523 Phase 4 Epiduo Gel;Duac Gel
42 Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris Completed NCT00752635 Phase 4 Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
43 Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face. Completed NCT00714714 Phase 4 Adapalene Gel;Tretinoin Gel
44 Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris Completed NCT00696449 Phase 4 Adapalene
45 Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris Completed NCT00671749 Phase 4 adapalene gel, 0.3%;clindamycin/benzoyl peroxide gel
46 Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1% Completed NCT00660985 Phase 4 Adapalene;Adapalene
47 Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne Completed NCT00658112 Phase 4 Benzoyl Peroxide
48 Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate Completed NCT00635609 Phase 4 Doxycycline hyclate (Doryx);Doxycycline hyclate
49 Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne Completed NCT00469755 Phase 4 Adapalene Gel, 0.1%;Tazarotene Cream, 0.1%;Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
50 Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1% Completed NCT00437151 Phase 4

Search NIH Clinical Center for Sebaceous Gland Disease

Genetic Tests for Sebaceous Gland Disease

Anatomical Context for Sebaceous Gland Disease

MalaCards organs/tissues related to Sebaceous Gland Disease:

39
Skin, Testes, Brain, Lymph Node, Bone

Publications for Sebaceous Gland Disease

Variations for Sebaceous Gland Disease

Expression for Sebaceous Gland Disease

Search GEO for disease gene expression data for Sebaceous Gland Disease.

Pathways for Sebaceous Gland Disease

GO Terms for Sebaceous Gland Disease

Cellular components related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 gamma-secretase complex GO:0070765 8.62 NCSTN PSENEN

Biological processes related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.8 CXCL8 DEFB4A IL1A TLR2
2 inflammatory response GO:0006954 9.73 CXCL8 IL1A PSTPIP1 TLR2
3 positive regulation of mitotic nuclear division GO:0045840 9.48 IGF1 IL1A
4 membrane protein ectodomain proteolysis GO:0006509 9.46 NCSTN PSENEN
5 membrane protein intracellular domain proteolysis GO:0031293 9.4 NCSTN PSENEN
6 Notch receptor processing GO:0007220 9.37 NCSTN PSENEN
7 cell activation GO:0001775 9.32 IGF1 TLR2
8 response to molecule of bacterial origin GO:0002237 9.26 CXCL8 TLR2
9 amyloid precursor protein metabolic process GO:0042982 9.16 NCSTN PSENEN
10 amyloid precursor protein catabolic process GO:0042987 8.96 NCSTN PSENEN
11 beta-amyloid formation GO:0034205 8.62 NCSTN PSENEN

Sources for Sebaceous Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....